FDA Status: Compounded Semaglutide and Tirzepatide are not FDA-approved
Tirzepatide was later approved by the FDA in November 2023 for chronic weight management in adults with obesity or overweight, who have at least one weight-related condition (e.g., high blood pressure, Type 2 diabetes, or high cholesterol), in addition to diet and exercise
Small lapses by untrained or rushed team members leaving vials open, mishandling packaging, or returning samples to the wrong temperature can accumulate into significant problems over time
These outcomes were characterized by greater callus development and increased mineralization within the affected area, indicating enhanced bone continuity and strength (21)
But its a simple, common-sense way to describe the hollow or sometimes sagging look people get when the pounds drop off faster than their skin can keep up
Noetel et al., 2024